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Ischemic stroke is a major cause of mortality and morbidity worldwide whose 
prevalence is set to increase driven by the ongoing epidemiologic shift (1, 2). Yet, 
therapeutic strategies are limited to the early restoration of blood flow which can, 
on the other hand, worsen brain damage trough ischemia/reperfusion (I/R) injury 
(3-5). Furthermore, due to the narrow treatment time window and the substantial 
number of contraindications only 1-2 out of 10 stroke patients are eligible for 
intravascular thrombolysis (6, 7). Safe and effective approaches to contain 
cerebral ischemic damage are long-term unmet medical needs and a better 
understanding of stroke pathophysiology is essential to identify novel molecular 
target to widen our interventional options in this setting. 
Standing at the interface between cerebral circulation and the brain parenchyma, 
the blood-brain barrier (BBB) regulates diffusion of solutes and protects the brain 
from circulating pathogens (8). Together with pericytes and astrocytes, cerebral 
microvascular endothelial cells critically control BBB permeability through the 
expression of different tight- and adherens-junctions (8). Following an ischemic 
stroke, I/R-mediated BBB disruption associates with vascular leakage and 
infiltration of circulating cells and solutes leading to edema and worsened 
parenchymal damage (3, 5, 8, 9). Accordingly, in ischemic stroke patients barrier 
impairment is associated with haemorrhagic transformation and worsened 
outcome (10-12) thus indicating BBB as a promising therapeutic target to blunt 
I/R-mediated cerebral injury. 
Aging is a major risk factor for stroke and several genes regulating lifespan were 
shown to determine cerebral damage in I/R brain injury (1, 13, 14). Specifically, 




biological processes such as aging, cell metabolism, redox balance, inflammation 
and apoptosis which are key to the pathophysiology of stroke (15, 16). SIRT6 is a 
involved in telomere/genome stabilization, DNA repair but also inflammation and 
glucose or fat homeostasis (17). Furthermore, SIRT6 is a well-recognized 
longevity gene where Sirt6 transgenic mice were shown to have an increased life 
span compared with wild-type controls (17). Through its negative regulator 
function on myocardial IGF-Akt signaling, Sirt6 deficiency results in cardiac 
hypertrophy and heart failure whereas SIRT6 overexpression increases hypoxia 
resistance in cardiomyocytes (17). The role of SIRT6 in brain disease has been 
inconclusively explored (18); indeed so far, a possible protective role has been 
suggested only for neuronal SIRT6 in a preclinical study (19). 
Given the pivotal role of endothelial cells in BBB function and the prognostic 
relevance of BBB damage in stroke patients, we hypothesized that the endothelial-
specific expression of the longevity gene SIRT6 may be protective in the setting of 
ischemic stroke. Accordingly, in this study we investigated whether specific 
deletion of endothelial Sirt6 affects cerebral damage in a mouse model of stroke. 
Also, we tested SIRT6 as a potential therapeutic target by post-ischemically 
inducing its expression in mice so as to mimic a clinically relevant experimental 
setup. Furthermore, to increase the translational relevance of our data, we assessed 
the relevance of SIRT6 in the barrier function using primary human brain 
microvascular endothelial cells (HBMVECs) exposed to hypoxia/reoxygenation. 
Finally, we assessed SIRT6 expression in ischemic stroke patients and correlated it 




MATERIAL AND METHODS 
Animals 
All mice were kept in a temperature-controlled animal facility under normal 
light/dark cycle with free access to food and water for the whole duration of the 
experiments herein described. All procedures were approved by the Committee 
for Animal Testing of the Canton of Zurich, Switzerland (license n. ZH114/18). 
Animal experiments were performed conform to the Directive 2010/63/EU of the 
European Parliament and of the Council of 22 September 2010 on the protection 
of animals used for scientific purposes. Animal experiments were reported 
according to Animal Research: Reporting in Vivo Experiments (ARRIVE) 
guidelines. 
Endothelial-specific Sirt6 knock-out mice 
Animal experiments were performed on 12-week-old endothelial-specific 
homozygous Sirt6 knockout (eSirt6-/-) male mice and age-matched Sirt6 floxed 
littermates (Sirt6fl/fl). Both groups were maintained on C57BL/6 background. 
eSirt6-/- mice were generated by crossbreeding Sirt6fl/fl mice with hemizygous 
mice overexpressing Cre-recombinase under control of vascular endothelial-
specific cadherine (Cdh5) promoter (Cdh5-CreTg/+). The presence of the Sirt6 
floxed and excised knockout allele as well as of Cre recombinase was confirmed 
by routine genomic PCR using following PCR primers: for Sirt6 floxed: 5’- AAC 
TGA CTG TTG CGG CAG AG-3’ forward, 5’-CCT GTC CCA TTC TGA GGA 
C-3’ reverse; for Sirt6 knockout: 5’- AAC TGA CTG TTG CGG CAG AG-3’ 
forward, 5’-GCT GGG ATT AAA GGC TGC G-3’; for Cre: 5’-AAC TGA CTG 




reverse. PCR products were visualized on either 4% (Sirt6) or 1.5% (Cre) agarose 
gel.  
Post-ischemic Sirt6 overexpression 
12-week-old C57BL/6 wild-type males treated with either cloning vector (pCMV) 
or Sirt6 cDNA clone (Sirt6) were used for post-ischemic Sirt6 overexpression 
experiments. Briefly, after 45 mins of ischemia and upon retraction of the 
occlusive filament (beginning of reperfusion) animals were randomly injected i.v. 
either with 40μg of cloning vector (Origene, PCMV6-Entry, PS100001) or a 
predesigned mouse Sirt6 cDNA clone (Origene, MC200652) together with a 
cationic transfection reagent jetPEI® (Polyplus TransfectionTM, New York, NY, 
USA), according to the manufacturer’s instructions (http://www.polyplus-
transfection.com), as previously described (20). In pilot experiments exploring the 
temporal dynamic of cDNA delivery, mice did not undergo transient middle 
cerebral artery (MCA) occlusion (tMCAO). Euthanasia was induced with carbon 
dioxide at different time-points after plasmid injection. Then, the animal was 
perfused with 10 mL cold PBS before harvesting vessels. Common carotid artery 
and MCA were identified using a dissecting microscope and excised in total. 
Isolation of endothelial cells 
Mice were perfused with PBS through the left ventricle; lung tissue, excluding 
central bronchi, was collected and minced with surgical blades. Then, it was 
incubated for one hour at 37 °C, under continuous agitation in a solution 
containing collagenase type 2 and dispase (Invitrogen). Digests were then passed 
through a 100 μm strainer and centrifuged at 400g. To remove red blood cells, 




separation medium, and the suspension was carefully layered on Ficoll-Paque 
(Amersham) and spun 400g for 20 min at 18°C without brakes. The interphase 
containing viable cells was then transferred into a fresh tube containing EC 
isolation medium. Finally, cells were sorted by using an anti-mouse CD31 
MicroBeads (Miltenyi Biotec) (21). 
Transient middle cerebral artery occlusion 
To induce I/R brain injury, tMCAO was performed as previously described (22, 
23). Briefly, mice were anaesthetized using isoflurane 3 % and 1.5 % for 
induction and maintenance respectively, while body temperature was kept at 
37°C. For analgesia, 0.5% bupivacaine was infiltrated at the incision side. 
Ischemia was induced by inserting a 6-0 silicone-coated filament (Doccol 
Corporation, Sharon, MA, USA) into the common carotid artery until the origin of 
the left MCA after the dissection of common, internal and external carotid 
arteries. After 45 minutes, reperfusion was allowed for 48 h before animal 
euthanasia with carbon dioxide. After euthanasia, peripheral blood was collected 
by intracardial puncture. Then, the animal was perfused with 10 mL cold PBS 
before harvesting brain and vessels. MCA origin was identified using a dissecting 
microscope and excised in total. The well-being of mice during the experimental 
period was determined using a score sheet that was approved by the Cantonal 
Veterinary Office of the Canton of Zurich. This score sheet was used to define 
survival/death of an animal. Death events include spontaneous deaths (1 of 17 for 






For determination of stroke volumes, murine brains were cut into 5 (2-mm thick) 
coronal sections and immersed in a 2% solution of 2,3,5-triphenyltetrazolium 
chloride (TTC) (Sigma-Aldrich, Chemie GmbH, Buchs, Switzerland) at 37°C for 
20 min. Stroke areas, were quantified using ImageJ Software (Image J, NIH, MD, 
USA). The following formula was applied in order to compensate for cerebral 
swelling (edema) and subsequent overestimation of the infarct volume as 
previously described (16): corrected infarct volume = contralateral hemisphere 
volume - (ipsilateral hemisphere volume - infarct volume). 
Neurological deficit assessment 
Neurological status was assessed 2, 24 and 48 h after tMCAO by a four-point 
scale neurological score based on Bederson et al. (24) as follows: grade 0, normal 
neurological function; grade 1, forelimb and torso flexion to the contralateral side 
upon lifting the animal by the tail; grade 2, circling to the contralateral side; grade 
3, leaning to the contralateral side at rest; grade 4, no spontaneous motor activity, 
as previously described (25). Neurological performance was determined by the 
RotaRod test: animals were placed on a rotating rod at increasing speeds (4–44 
revolutions/min) and latency to fall was recorded (26).  
Immunohistology 
Immunohistological stainings of infarcted brains were performed as previously 
described (16). Briefly, following induction of deep anesthesia, mice were 
transcardially perfused with phosphate buffered saline (PBS) (Sigma-Aldrich, 
Chemie GmbH, Buchs, Switzerland). The brains were removed and consecutively 
incubated overnight in 4.0% PFA at 4 °C and afterwards transferred to 30% 




floating sections pre-treated with proteinase K for antigen retrieval and immune-
blocked. After these, sections were incubated with primary antibodies at the 
following dilution: the endothelial marker CD31 (550274; 1:50; BD Pharmingen, 
Allschwil, Switzerland), SIRT6 (#12486S; 1:50; Cell Signalling Technology, 
Danvers, MA, USA) and cleaved caspase-3 (#9664S; 1:400; Cell Signalling) at 
4ºC overnight, respectively. After washing, brain sections were incubated with the 
appropriate secondary antibodies (Jackson Immunoresearch, West Grove, PA, 
USA) for 24 h at room temperature. Images were acquired using a confocal 
microscope (Leica SP8; Leica, Wetzlar, Germany). Stained area of Sirt6 and 
cleaved caspase-3 was measured using ImageJ Software and normalized to the 
total endothelial cell surface assessed by CD31 staining. 
BBB permeability was measured assessing endogenous immunoglobulin G (IgG) 
extravasation, sections were blocked for 60 min followed by incubation with 
Alexa647-conjugated donkey anti-mouse IgG for 24 h (715-605-151; 1:600; 
Jackson Immunoresearch, West Grove, USA). IgG leakage was corrected for 
edema, as previously described in stroke volume assessment, and expressed as a 
percentage of the total contralateral hemisphere volume. 
Cell culture experiments 
Primary human brain microvascular endothelial cells (HBMVECs) (Cell Systems, 
Kirkland, WA, USA) between passages 6 and 8 were used for in vitro 
experiments. Endothelial cells were cultured in Endothelial Cell Growth Medium 
(Cell Applications Inc., San Diego, CA, USA), supplemented with and 10% fetal 
bovine serum (BSA, Thermo Fisher Scientific, Waltham, MA, USA). Cells were 
grown to 80 % confluence before being transfected with SIRT6 small interfering 




Microsynth, Balgach, Switzerland) for 24 h using the Lipofectamine® 3000 
transfection kit according to manufacturer’s recommendations (Invitrogen, 
Carlsbad, CA, USA). Next, cells were exposed to hypoxia (0.2% oxygen) for 4 h 
followed by 4 h of normoxia (21% oxygen) (reoxygenation) or kept at normoxic 
conditions (21% oxygen) for 8 h, as previously shown (27). Hypoxia was induced 
using a gas-controlled glove hypoxia workstation (Invivo2 400, Baker Ruskinn, 
Sanford, ME, USA). 
Measurement of Barrier Function by Transendothelial Electrical Resistance 
Measurements of transendothelial electrical resistance (TEER) on HBMVEC 
monolayers were performed using the electric cell-substrate impedance system 
(ECIS) Z Theta system (Applied Biophysics, Troy, NY, USA) as previously 
described (16). The ECIS system provides real-time monitoring of changes in 
TEER. In brief, HBMVECs at 9x105/well were plated on fibronectin coated 
8W10E+ electrode arrays (Applied Biophysics). Then, cells were allowed to form 
monolayers until stable TEER values were reached. After 5 h, the monolayers 
were treated with SIRT6 or scramble siRNA as previously specified. Then, they 
were exposed to hypoxic conditions for 4 h followed by reoxygenation for 48 h. 
Measurements were conducted at multiple frequencies ranging from 62.6 Hz to 64 
kHz. Data were expressed as TEER percent change from baseline values (average 
of last 3 measurements before hypoxia). 
Western blotting 
Protein expression was determined by Western blot analysis . Murine vessels and 
endothelial cells a were lysed (Tris 50 mM, NaCl 150 mM, EDTA 1 mM, NaF 1 




phenylmethylsulfonyl fluoride (PMSF) 1 mM, and NP-40 0.5%) and total protein 
concentration was determined according to the manufacturer’s recommendations 
(Bio-Rad Laboratores AG, Fribourg, Switzerland); 20 – 30 µg of total protein 
lysates were separated on an 8 or 10% SDS–PAGE before being transferred to a 
polyvinylidene fluoride membrane by wet transfer (Bio-Rad Laboratores AG, 
Fribourg, Switzerland). Membranes were incubated with primary antibodies 
against SIRT6 (#12486S; 1:1000; Cell Signalling), cleaved caspase-3 (#9661S; 
1:1000; Cell Signalling), phospho-Akt (#4060S; 1:1000, Cell Signaling), Akt 
(#9272S; 1:1000, Cell Signaling) and glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) (MAB374; 1:40000; Merck Millipore, Billerica, MA, USA) over night 
at 4°C on a shaker. Secondary antibodies anti-mouse (1031-05) and anti-rabbit 
(4050-05) were obtained from Southern Biotechnology (Birmingham, AL, USA) 
and applied for 1 h at room temperature. Densitometric analyses were performed 
(Amersham Imager 600, General Electric; Healthcare Europe GmbH, Glattbrugg, 
Switzerland) and protein expression was normalized to GAPDH (SIRT6 and 
cleaved caspase 3) or total Akt (phospho-Akt). 
Cytotoxicity Detection 
Lactate dehydrogenase (LDH) release was determined in supernatant from 
cultured HBMVECs according to manufacturer’s recommendations (Cytotoxicity 
Detection Kit; Roche, Basel, Switzerland). Briefly, enzymatic activity of 
cytoplasmic LDH released from dead cells was detected by conversion of NAD+ 
to NADH/H+ and subsequent reduction of Iodotetrazolium chloride to formazan 
(red). Absorbance was determined at 490 nm using an enzyme-linked 






Endothelial cell lysates were centrifuged at 10,000 g to remove insoluble material. 
For immunoprecipitation, precleared lysates were incubated with Akt antibody 
overnight at 4°C. Lysates were precleared by incubation with 50 μL of protein 
A/G-agarose for 4 h at 4°C with rocking. Agarose beads were pelleted by 
centrifugation at 1000 g. Immunoprecipitated proteins were eluted from the beads 
by boiling for 5 min in SDS sample buffer and immunoblotted with primary 
antibodies against Akt (1:1000) and SIRT6 (1:1000). Bound antibody was 
visualized using an enhanced chemiluminescence system (Merck Millipore, 
Billerica, MA, USA) after incubation with peroxidase-conjugated secondary 
antibody for 1 h. 
Patients 
Ischemic stroke patients (n=14) admitted to the emergency room of San Raffaele 
Hospital (OSR, Milan, Italy) within 6 h after symptom onset were enrolled in the 
present study. Patients diagnosed with diabetes, systemic inflammatory diseases, 
acute infections, and active malignancy were excluded to eliminate potential 
interference of those disease states on SIRT6 expression. Venous blood was 
collected 24 h after initial stroke symptoms. Of the 14 ischemic stroke patients, 5 
received intravascular thrombolytic treatment with recombinant tissue 
plasminogen activator within 4.5 h from initial symptom onset. Ischemic strokes 
were diagnosed based on clinical history, neurological examination and a brain 
computed tomography scan at arrival in the emergency department; stroke 
aetiology was defined according to the Trial of ORG 10172 in Acute Stroke 
Treatment (TOAST) criteria (28). MCA occlusion was defined according to the 




volume was measured at follow-up non-contrast CT scan by using the formula 
ABC/2 according to an ellipsoid model (A: longest dimension in axis x, B: longest 
perpendicular dimension to axis x (y), C: total length in z dimension) (30). Stroke 
severity was assessed using NIHSS on hospital admission and at discharge. 
Furthermore, ΔNIHSS% was calculated as the difference between the NIHSS 
presented at discharge and the NIHSS presented at admission relativized on initial 
NIHSS [ΔNIHSS = (NIHSS discharge − NIHSS admission) / NIHSS admission]; 
thereby, positive values indicate short-term neurologic worsening while negative 
values indicate neurological improvement. The study was approved by the local 
Ethics Committee at San Raffaele Scientific Institute, Milan, Italy and was 
performed conform to the declaration of Helsinki. All participants (or their 
representative relatives) provided signed informed consent. 
Isolation of peripheral monocytes from study subjects 
Monocytes from whole blood were isolated using anti-CD14-coated MicroBeads 
(Miltenyi Biotec, Bergisch Gladbach, Germany) on a magnetic separator 
(Miltenyi Biotec, Bergisch Gladbach, Germany), as previously described (31).  
Real-time PCR 
Real-time PCR have been applied to assess gene expression in patients’ 
monocytes as previously described (27). Total RNA was extracted from patients’ 
monocytes using TRI Reagent (Merck KGaA, Darmstadt, Germany) according to 
the manufacturer’s recommendations. Conversion of the total cellular RNA to 
cDNA was performed with Moloney murine leukemia virus reverse transcriptase 
and random hexamers (GE Healthcare, Little Chalfont, UK) in a final volume of 




RT-PCR was performed in a QuantStudio 7 Flex RT-PCR cycler (Applied 
Biosystems, Foster City, CA, USA) according to the manufacturer’s instructions. 
All RT-PCR experiments were performed using the SYBR Select Master Mix 
provided by Applied Biosystems (Life Technologies, Carlsbad, CA, USA). Each 
reaction (20 μl) contained 2 μl cDNA, 400 fmol of each primer and 10 μl of 
Master Mix. The following primers was used (all from Microsynth): for hSIRT6: 
forward 5’-GCT TCC TGG TCA GCC AGA-3’, reverse 5’-CTT GGC ACA TTC 
TTC CAC AA-3’; for actin β (hACTB): forward: 5’-GCA CAG AGC CTC GCC 
TT-3’ and reverse: 5’-GTT GTC GAC GAC GAG CG-3’. The amplification 
program consisted of 1 cycle at 95˚C for 10 min, followed by 40 cycles with a 
denaturing phase at 95˚C for 15 s, an annealing/elongation phase at 60˚C for 1 
min. A melting curve analysis was performed after amplification to verify the 
accuracy of the amplicon. Cycle threshold (Ct) values for each gene were 
obtained for each sample and analysed with Graph Pad Prism 6 software 
(GraphPad Software, Inc, La Jolla, CA, USA). Differences in CT values (ΔCT) 
between the test gene and the endogenous housekeeping control (hACTB) were 
calculated and used for statistical analyses. 
Statistical analysis 
Data are expressed as mean ± standard deviation (SD). All statistical analyses 
were performed using GraphPad Prism 6 software (GraphPad Software, Inc, La 
Jolla, CA, USA). Data were analysed by using unpaired two-tailed Student’s t-test 
to compare two independent groups, Cohen’s d was calculated as measure of the 
effect size and expressed as d and 95% (confidence interval) CI (32). For repeated 
measurements, two-way ANOVA with Sidak post hoc test was used. Fisher’s 




Pearson’s correlation analysis was used to test the correlation between two 
quantitative variables. Statistical analysis for survival studies was performed using 
log-rank (Mantel-Cox) test. A probability value (P) below or equal 0.05 was 





Generation of the endothelial-specific Sirt6 knockout mice 
Endothelial-specific Sirt6 homozygous knockout mice were generated by 
crossbreeding Sirt6fl/fl mice with hemizygous mice overexpressing Cre-
recombinase under control of vascular endothelial-specific cadherine (Cdh5) 
promoter (Cdh5-CreTg/+)(Fig. 1A). In the resulting Sirt6fl/fl Cdh5-CreTg/+ double 
mutant animals, the Sirt6 sequence flanked by two loxP sites is excised by Cre-
mediated recombination in the endothelium thus leading to selective deletion of 
Sirt6. The endothelium-specific removal of the flanked region was confirmed on 
isolated murine endothelial cells by genomic PCR using Sirt6- and Cre-specific 
primers (Fig. 1B). At the time of experiment, eSirt6-/- and Sirt6fl/fl littermates did 
not show any difference in terms of blood pressure and fasting lipid or glucose 
levels (data not shown). 
 
Brain ischemia/reperfusion reduces endothelial SIRT6 expression in cerebral 
vessels 
To test the responsiveness of vascular SIRT6 to stroke in vivo, tMCAO was 
performed in SIRT6fl/fl mice for 45 minutes followed by 48 h of reperfusion. Next, 
endothelial SIRT6 expression after stroke was assessed by co-staining SIRT6 with 
CD31 - an endothelial specific protein - in the infarcted penumbra area and 
compared to that of the unaffected contralateral hemisphere. I/R injury strongly 
reduced expression of SIRT6 in vessels from the ipsilateral hemisphere, as 
compared to those located in the contralateral one (d=1.04 (95%CI 0.04-2.04); 




Endothelial-specific Sirt6 deletion worsens ischemia/reperfusion-induced 
cerebral damage and post-stroke outcome in mice.  
To evaluate the relevance of endothelial Sirt6 in cerebral I/R injury, eSirt6-/- mice 
underwent tMCAO. Following 45 minutes of ischemia and 48 h of reperfusion 
(Fig. 2B) eSirt6-/- mice revealed increased infarct volumes compared to control 
animals, as assessed by TTC staining (d=1.75 (95%CI 0.68-2.81); P=0.005; Fig. 
2C). Accordingly, survival 48 h after tMCAO was significantly reduced in eSirt6-
/- as compared to Sirt6fl/fl littermates (68% vs. 94%, P=0.046; Fig. 2D). Also, post-
stroke neurological deficits have been quantified by two different tests at different 
time-points. At baseline, eSirt6-/- mice and Sirt6fl/fl littermates showed no 
differences in terms of neurological- and motor-function, as assessed by RotaRod 
test and Bederson-based neurological index (Fig. 2E and 2F). 24 h and 48 h after 
stroke, eSirt6-/- mice displayed a significantly shorter latency to fall from the 
rotating rod compared to Sirt6fl/fl animals, indicating a greater impairment of 
motor function (P=0.004 and P= 0.010, respectively; Fig. 2E). In line with this, 
also the neurological deficits according to the Bederson-based scale were 
significantly worsened in eSirt6-/- mice than in control littermates at both 24 and 
48 h after the experiment (P=0.001 and P<0.0001, respectively; Fig. 2F).  
Post-ischemic Sirt6 overexpression reduces ischemia/reperfusion-induced 
cerebral damage 
To test the potential of SIRT6 as a therapeutic target in the setting of ischemic 
stroke, we induced Sirt6 overexpression in WT mice. In vivo overexpression of 
SIRT6 was performed by intravenous injection of a predesigned cDNA clone 
(Sirt6) together with a cation transfection reagent. Already 24 h after the injection 




at least 96 h, as compared to control animals receiving cloning control vector 
(pCMV) (Fig. 3A).  
In order to reproduce a clinically relevant experimental setup, Sirt6 
overexpressing clone was injected after the ischemic event, upon reperfusion thus 
mimicking the situation of patients presenting to the emergency care unit with 
ischemic stroke and eligible for thrombolytic therapy (Fig. 3B). Despite the post-
ischemic treatment, SIRT6 overexpression led to a drastic reduction in stroke size 
of more than 50% at 48 h after tMCAO (d=4.18 (95%CI 2.96-5.40); P<0.0001; 
Fig. 3C). Accordingly, post-ischemic Sirt6 overexpression also blunted 
neurological impairment at 24 and 48 h of reperfusion as assessed by both 
RotaRod test and Bederson index (P=0.010 and P=0.016 for RotaRod test and 
P=0.042 and P=0.007 for Bederson index; Fig. 3D and 3E, respectively).  
The successful cDNA delivery have been confirmed also in MCA lysates (Fig.4) 
Endothelial-specific Sirt6 deletion increases BBB disruption and caspase 3 
activation. 
To assess BBB impairment, IgG immunohistochemistry was performed on brain 
sections. Both eSirt6-/- and Sirt6fl/fl animals showed IgG leakage in the ipsilateral 
hemisphere 48 h after tMCAO, whereas no IgG staining was found in the 
contralateral side (Fig. 5A). eSirt6-/- mice displayed aggravated BBB disruption 
upon I/R, as confirmed by increased extravasation of IgG as compared to Sirt6fl/fl 
littermates (d=1.39 (95%CI 0.35-2.44); P=0.019; Fig. 5A).  
Brain microvascular endothelial cells constitute the backbone of the BBB 
structure, their death or apoptosis after I/R injury affects BBB integrity and thus 




caspase-3 – the common mediator of caspase-dependent apoptotic cascade (34) – 
in brain slices by immunostaining. Coherently to the higher BBB impairment, 
eSirt6-/- mice also showed increased levels of cleaved-caspase-3 related to 
endothelial cells in the penumbra area as compared to control littermates 
suggesting a higher apoptosis rate in response to I/R damage (d=1.33 (95%CI 
0.59-2.38); P=0.023; Fig. 5B). 
Impaired barrier function, increased cell death and caspase-3 activation in 
SIRT6-silenced primary HBMVECs after hypoxia/reoxygenation 
To test the translational relevance of our in vivo findings, primary human brain 
microvascular endothelial cells (HBMVECs) were exposed to hypoxia for 4 h 
followed by 4 h of reoxygenation. In line with the observed downregulation of 
endothelial SIRT6 following I/R in murine cerebral vessels, we observed reduced 
SIRT6 expression in primary HBMVECs after exposure to hypoxia/reoxygenation 
(d=2.51 (95%CI 1.35-3.67); P=0.001; Fig. 6A). To confirm the role of endothelial 
SIRT6 in stroke mediated BBB impairment, we assessed the barrier function of 
SIRT6-silenced cells (siSIRT6) exposed to hypoxia /reoxygenation (4h/48h, 
respectively) by using an established in vitro BBB model consisting of a 
monolayer of HBMVECs seeded at confluence in ECIS electrode chambers. 
SIRT6 silencing in HBMVECs was achieved by transfection with SIRT6 siRNA 
(siSIRT6) as compared to siSCR-treated cells (d=5.77 (95%CI 4.22-7.32); 
P<0.0001; Fig. 6B). SIRT6 silencing did not affect cell death rate under normoxic 
conditions (data not shown). In line with the increased BBB impairment observed 
in eSirt6-/- animals after stroke, siSIRT6 cells showed lower trans-endothelial 
resistance compared to siSCR after hypoxia/reperfusion thus suggesting a higher 




Reflecting the increased endothelial cleaved-caspase 3 expression in cerebral 
Sirt6-deficient vessels after stroke, increased cell death rate and caspase-3 
activation was also confirmed in SIRT6-silenced HBMVECs exposed to 
hypoxia/reoxygenation (d=1.52 (95%CI 0.43-2.61) and P=0.015 for LDH assay 
and d=1.32 (95%CI 0.24-2.40) and P=0.029 for caspase 3 activation; Fig. 6D-E). 
By acting on several downstream targets, Akt pathway is a known regulator of 
cell survival under stress conditions in different cells, including endothelial ones 
(35). In line with its critical anti-apoptotic properties, here we report reduced Akt 
phosphorylation in SIRT6-silenced endothelial cells after hypoxia/reoxygenation 
as compared to siSCR ones (d= 1.55 (95%CI 0.46-2.65); P=0.013; Fig. 6F). To 
confirm the involvement of SIRT6 in the regulation of Akt pathway, we 
performed a co-immunoprecipitation experiment. First, we found that SIRT6 co-
immunoprecipitates with Akt (Fig. 6G). Furthermore, we observed a reduction of 
the direct protein-protein interaction after exposure to hypoxia/reoxygenation by 
approximately 2 fold (Fig. 6G). 
Monocyte SIRT6 gene expression in patients with ischemic stroke correlates 
with short-term outcome 
To substantiate the translational relevance of our data, we analysed SIRT6 
expression levels in monocytes of ischemic stroke patients. In light of the fact that 
endothelial cells could not be easily obtained, we chose monocytes as a surrogate 
cell type. A total of 14 ischemic stroke patients were included in the analysis, 
patients were then divided in those presenting a short-term neurological 
improvement (ΔNIHSS%<0) and those with a worsening of neurologic functions 
(ΔNIHSS%>0). Clinical characteristics of the whole cohort are showed in Table 




distribution, risk factors and comorbidity (Table 1). In ischemic stroke patients, 
SIRT6 mRNA levels were significantly higher in patients showing short-term 
neurological improvement as compared to unfavourable short-term outcome 
(d=1.33 (95%CI 0.25-2.41); P=0.029; Fig. 7A). Furthermore, a negative 
correlation was found between SIRT6 transcript levels at 24 h from onset of 
symptoms and the ΔNIHSS% as a measure of short-term neurological outcome 





Ischemic stroke is an age-related disease with limited treatment options whose 
incidence is set to increase with the ongoing demographic changes (1, 2, 5). In an 
effort to deepen our knowledge of the molecular networks underlying age-
dependent cardio- and cerebro-vascular disease to identify novel therapeutic 
target, we previously investigated the role of different aging and longevity genes 
in the setting of stroke (16, 25, 26, 36). Recently, SIRT6 has been reported as a 
longevity gene in mice, primates and humans (37-39). Given the pivotal role of 
endothelial cells in BBB function and the prognostic relevance of BBB damage in 
stroke patients, we investigated for the first time the specific function of 
endothelial SIRT6 in stroke using animal models, human primary cells and 
samples from ischemic stroke patients.  
In this study, we demonstrate for the first time that endothelial SIRT6 improves 
outcome after cerebral ischemia/reperfusion injury and that it may represent an 
interesting novel therapeutic target. Several experimental data substantiate our 
conclusions: (i) SIRT6 expression is reduced in the murine cerebrovasculature 
after I/R injury as well as in primary HBMVECs exposed to 
hypoxia/reoxygenation; (ii) endothelial-specific Sirt6 genetic deletion increases 
stroke size and decreases post-stroke survival and neurological deficit by 
exacerbating apoptosis and BBB dysfunction; (iii) in vivo post-ischemic Sirt6 
overexpression blunts stroke-induced cerebral damage and improves outcome; 
(iv) SIRT6 silencing impairs barrier function in primary HBMVECs exposed to 
hypoxia/reoxygenation blunting the activation of Akt salvage pathway and 




stroke patients with short-term neurological improvement and correlates with 
stroke outcome.  
A large body of evidence links SIRT6 to longevity as well as to age-dependent 
disease. SIRT6 prevents premature cell senescence by stabilizing the genome and 
preserving telomeres (40, 41). In rodents, SIRT6 overexpression increases 
lifespan while its deletion is associated to premature aging (42-44). Recently, 
SIRT6 was reported to be protective in endothelial dysfunction, atherosclerosis 
and cardiac hypertrophy (45-47). Furthermore a protective role for SIRT6 was also 
postulated in brain degenerative disease as its expression is reduced in brains of 
aged animals and Alzheimer’s diseases models and, this reduction is associated to 
neuronal genome instability, cell death, and hyper phosphorylation of tau proteins 
(48-51). Also, SIRT6 was reported to protect neuronal viability in response to 
oxygen-glucose deprivation, an in vitro model of I/R injury (52, 53). Given the 
important role of microvascular endothelial cells in BBB function and stroke 
outcome, in this study we focused on endothelial Sirt6 and found its levels to be 
reduced in cerebral endothelial cells of brains exposed to I/R and in primary 
HBMVECs exposed to hypoxia/reoxygenation. These findings suggest that 
endothelial SIRT6 might be involved in I/R-mediated damage and add novel 
information to endothelial responses to hypoxic condition. Although, this is in line 
with previous reports on other cell types (52-55), the exact mechanisms mediating 
SIRT6 decrease in response to ischemia and hypoxia remain incompletely 
understood. Hypoxia-inducible factor (HIF)-1α-mediated downregulation of 
SIRT6 expression might be a mediator of SIRT6 decrease since a strong interplay 




In our experiments, endothelial Sirt6 deletion associates with increased cerebral 
damage and neurological impairment as well as with decreased survival following 
I/R brain injury, complementing what has been already shown in cardiomyocytes 
and hepatic cells by other groups (58, 59). Furthermore, our findings are 
reinforced by the observation that Sirt6 overexpression reduces brain injury and 
improves outcome after tMCAO. Of interest in this latter experiment, SIRT6 
expression was post-ischemically induced in animals, upon reperfusion so as to 
mimic the clinical scenario where patients presenting to the emergency room and 
eligible for reperfusion interventions could be simultaneously treated with 
additional therapeutic agents. Also, the Sirt6-overexpressing construct was 
administered intravenously and not via intracerebroventricular injection as 
previously done (52), further endorsing the clinical relevance of our experimental 
set up.  
BBB disruption as a result of I/R damage determines stroke size and associates to 
worsen clinical outcome. In this study, we could show that endothelial barrier 
function after ischemia/hypoxia is deeply impaired by SIRT6 depletion both in 
animals and primary human cells. Indeed, immunohistochemistry analysis of 
brain slices demonstrates higher extravasation of macromolecules (IgG) -a 
hallmark of BBB dysfunction- in the ipsilateral hemisphere of eSIRT6-/- animals 
as compared to control littermates. Mirroring the in vivo data, SIRT6 silencing 
reduced trans-endothelial resistance -an indicator of barrier function- in our in 
vitro BBB model consisting of primary HBMVECs exposed to 
hypoxia/reoxygenation. As for mechanisms, our in vivo and in vitro data 
consistently point toward an increased apoptosis in endothelial cell exposed to I/R 
when SIRT6 is lacking. By co-immunostaining an endothelial marker (CD-31) and 




brains, we showed higher levels of cleaved-caspase 3 related to endothelial cells 
in eSirt6-/- mice after tMCAO as compared to control littermates. While in vitro, 
SIRT6-silenced primary HBMVECs show increased death rate and increased 
cleaved-caspase 3 expression after exposure to hypoxia reoxygenation, as 
assessed by LDH assay and western blot respectively. The role of SIRT6 in 
regulation of apoptosis is still matter of debate as both pro- and anti-apoptotic 
effects have been reported via modulation of different transcription factors (e.g. 
NF-κB, HIF1 and c-MYC) (44), particularly SIRT6 effects may depend on the 
cell type as SIRT6 have been reported to induce apoptosis in cancer cells but not 
in normal ones (60). Here we found that in HBMVECs exposed to 
hypoxia/reoxygenation SIRT6 deletion associates with reduced activation of the 
Akt salvage pathways, a known negative regulator of apoptosis (35). Also, we 
report that SIRT6 co-immunoprecipitate with Akt implying a direct protein-
protein interaction. Of interest, binding of SIRT6 to Akt was reduced in cells after 
exposure to hypoxia/reoxygenation. Originally described as a nuclear chromatin-
associated deacylase with histone post-translational modification, nowadays 
SIRT6 is known to localize also in the cytoplasm where it may regulate different 
pathways (61-63). Of note, previous research demonstrates that the deacetylase 
function of sirtuins (i.e. SIRT1 and SIRT2) facilitate Akt activation in different 
cell types (64, 65), this specific effect remains to be investigated for SIRT6 in 
endothelial cells. Nonetheless, a direct interaction between SIRT6 and Akt was 
previously shown in embryonic cell lines not exposed to hypoxia/reoxygenation 
(66).    
In order to increase the translational relevance of our preclinical findings, we 
investigated SIRT6 expression also in ischemic stroke patients. Here, the isolation 




from whole blood were selected as a surrogate cell type to investigate the 
relationship between SIRT6 and stroke outcome. SIRT6 mRNA levels were 
increased in ischemic stroke patients showing a short-term neurologic 
improvement compared to those who showed a worsening. Also, a linear 
correlation was found between SIRT6 expression and short term neurologic 
function. This data are in line with in vivo and in vitro data herein reported thus 
supporting the concept of SIRT6 being a positive regulator of stroke outcome. 
Some limitations should be taken into consideration when interpreting the herein 
reported data. First, although we previously demonstrated that in vivo cell 
transfection by mean of cationic reagent (e.g. jetPEI®) primarily targets 
endothelium in the brain (26), we cannot exclude that other cell types concur to 
determine the results showed in SIRT6 overexpression experiments. Second, the 
exact molecular mechanisms linking SIRT6 deficit to blunted activation of Akt 
salvage pathway following hypoxia/reoxygenation remain unclear. However, a 
direct deacetylase function of SIRT6 on Akt is a likely mechanism in this case. 
Finally, monocytes were chosen as surrogate cells for studying SIRT6 expression 
in ischemic stroke patients given the difficulty of obtaining cerebrovascular 
specimens. Clearly, results from this proof of principle experiment are purely 
associative and will require additional confirmatory investigations aiming at 
assessing the cause and effect relationship thus supporting our conclusions 





In conclusion, this translational study indicates that endothelial SIRT6 exerts a 
beneficial role in cerebral ischemia/reperfusion injury by preserving blood-brain 
barrier integrity. At the molecular level, SIRT6 might modulate I/R-induced 
apoptosis by reducing caspase-3 activation through the Akt salvage pathways. 
Data from this study set the stage for further investigation to validate endothelial 
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Demographic, risk factors and 
comorbidities 
    
Age, years (range) 73.3 (54-90) 68.0 (57-90) 78.6 (70-85) 0.053 
Female, n (%) 6 (42.9%) 2 (28.6%) 4 (57.1%) 0.280 
Smoking, n (%) 5 (35.7%) 3 (42.9%) 2 (28.6%) 0.593 
Hypertension, n (%) 8 (57.1%) 3 (42.9%) 4 (57.1%) 0.577 
Dyslipidemia, n (%) 1 (7.1%) 1 (14.3%) 0 (0%) 0.299 
Diabetes, n (%) 0 (0%) 0 (0%) 0 (0%) 1.000 
Coronary artery disease, n (%) 3 (21.4%) 2 (28.6%) 1 (14.3%) 0.515 
Previous TIA/stroke, n (%) 1 (7.1%) 1 (14.3%) 0 (0%) 0.299 
Peripheral artery disease, n (%) 4 (28.6%) 2 (28.6%) 2 (28.6%) 1.000 
Thrombolysis, n (%) 5 (35.7%) 3 (42.9%) 2 (28.6%) 0.593 
TOAST classification     
Large vessel atherosclerosis, n (%) 3 (21.4%) 1 (14.3%) 2 (14.3%) 0.515 
Cardioembolism, n (%) 7 (50%) 3 (42.9%) 4 (57.1%) 0.577 
Small vessel disease, n (%) 1 (7.1%) 1 (14.3%) 0 (0%) 0.299 
Undetermined cause, n (%) 1 (7.1%) 1 (14.3%) 0 (0%) 0.299 
Other cause, n (%) 2 (14.3%) 1 (14.3%)# 1 (14.3%)* 1.000 
Stroke assessment     
NIHSS admission, mean (SD) 10.6 (5.6) 8.9 (5.0) 12.4 (6.5) 0.383 
NIHSS discharge, mean (SD) 10.6 (10.3) 3.3 (2.3) 18.0 (10.8) 0.007 
Stroke size, mL (SD) 40.1 (59.5) 17.4 (18.2) 62.7 (78.4) 0.535 
MCA occlusion, n (%) 7 (50.0%) 4 (57.1%) 3 (42.9%) 0.577 
Early complications     
Haemorrhagic transformation, n (%) 0 (0%) 0 (0%) 0 (0%) 1.000 




TIA = Transient Ischemic Attack. 
NIHSS = National Institute of Health Stroke Scale 
MCA = Middle Cerebral Artery 








Figure 1. Generation and characterization of endothelial-specific SIRT6 knock out 
mice (A) Schematic representation of the targeting strategy for the genetic deletion of 
Sirt6 gene. (B) Genomic PCR on endothelial cells isolated from either endothelial-
specific Sirt6 homozygous knockout mice (eSirt6-/-) or corresponding controls (Sirt6fl/fl) 
using Sirt6-specific primers P1 and P3 (left panel), Cre-specific primers (middle panel) 
or Sirt6-specific primers P1 and P2 (right panel). The position of the corresponding PCR 
product is shown by arrows. (C-G) Circulating levels of total cholesterol, low-density 
lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides and glucose did 






Figure 2. Impact of endothelial Sirt6 deletion on cerebral lesion, survival and 
neurological deficit after tMCAO in mice. (A) After tMCAO, SIRT6 expression (red) 
relative to endothelial cells (cyan for CD31) is reduced in vessel located in the ipsilateral 
hemisphere as compared to the contralateral ones (representative images and 
quantification; n=8). (B) Schematic of experimental set up. (C) eSirt6-/- mice showed 
increased stroke volumes (representative pictures and quantification; n=7-8), (D) reduced 
survival at 48 h (n=17-22) and decreased neurological functions as assessed by (E) 
RotaRod or (F) Bederson-based neurological score (n=17-22), as compared to Sirt6fl/fl 
littermates. CD: cluster of differentiation; eSirt6-/-=endothelial-specific Sirt6 knock out 







Figure 3. Effects of post-ischemic Sirt6 overexpression on cerebral damage and 
neurological deficit after tMCAO. (A) Arterial SIRT6 expression is increased by about 
3 folds 24 h after the injection of Sirt6 construct (Sirt6), as compared to animals treated 
with control construct (pCMV) (quantification and representative blot; n=2). (B) 
Schematic of clinically relevant experimental set up in which the expression of Sirt6 have 
been induced in WT C57BL/6 animals vivo at the beginning of the reperfusion. (C) Post-
ischemic administration of the Sirt6 construct decreases stroke volume 48 h after tMCAO 
(representative pictures and quantification) and blunted neurological deficit as assessed 
by (D) RotaRod and (E) Bederson-based neurological scale, as compared to animals 
treated with control construct (pCMV) (n=8 for all). GAPDH=glyceraldehyde 3-






Figure 4. SIRT6 cDNA delivery to middle cerebral arteries (MCAs) (A) MCA SIRT6 
expression is increased by about 3 folds 24 h after the injection of Sirt6 construct (Sirt6), 








Figure 5. Impact of endothelial Sirt6 deletion on BBB damage and endothelial 
apoptosis after tMCAO. (A) At 48 h after stroke eSirt6-/- animals showed increased IgG 
extravasation (red) in the ipsilateral hemisphere denoting a higher BBB impairment, as 
compared to control littermates (SIRT6fl/fl) (representative picture of immunostaining and 
quantification; n=7-8). (B) After stroke, cleaved caspase-3 (cyan) expression relative to 
endothelial cells (red for CD31) is increased in the penumbra area of eSirt6-/- animals, as 
compared to Sirt6fl/fl control littermates (representative picture of immunostaining and 
quantification; n=7-8). CD= cluster of differentiation; eSirt6-/-=endothelial-specific Sirt6 
knock out animals; IgG= immunoglobulin G; SIRT6fl/fl=Sirt6-floxed control animals; 






Figure 6. SIRT6 responsiveness and effects of SIRT6 silencing on barrier function, 
cell death and apoptosis in primary HBMVECs after hypoxia/reoxygenation. (A) 
SIRT6 expression is reduced in primary HBMVECs after exposure to 
hypoxia/reoxygenation (4 h/4 h), as compared with normoxia (8 h) (n=7). (B) In 
HBMVECs, SIRT6 protein expression (n=7) is significantly reduced after transfection 
with SIRT6 small interfering RNA (siSIRT6) as compared to control siRNA (siSCR) 
(n=7). (C) SIRT6 silencing reduces endothelial barrier function as assed by continuous 
trans-endothelial resistance measurement (n=11). (D) Endothelial cell death in siSIRT6-
transfected HBMVECs was increased, compared with siSCR-treated cells after exposure 
to hypoxia/reoxygenation (n=7). (E) Activated (cleaved) caspase-3 protein expression 
was upregulated in SIRT6-transfected HBMVECs, compared with siSCR-transfected 
ones after exposure to hypoxia/reoxygenation (n=7). (F) siSIRT6-treated cells showed 
reduced activation of the Akt salvage pathway (n=7). (G) Representative immunoblot of 
co-immunoprecipitation of Akt and SIRT6 from whole-cell lysates of siSCR-treated cells 




dehydrogenase, H/R=hypoxia/reoxygenation, HBMVECs=human brain microvascular 







Figure 7. SIRT6 gene expression in patients with ischemic stroke and its correlations 
with the short-term outcome. (A) Monocyte SIRT6 mRNA expression is increased in 
ischemic stroke patients showing short-term neurological improvement (ΔNIHSS%<0) as 
compared to those with worse outcome (ΔNIHSS%>0) (n=14). (B) In ischemic stroke 
patients there is a linear correlation between SIRT6 transcript levels and short-term 
neurological outcome as assed by the neurological deficit assessed by the National 
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